Healthpeak Properties (DOC) Financials

Healthpeak Properties’ financial profile shows steady revenue growth and strong operating cash generation, but earnings remain volatile and leverage has increased. The company’s reported results also include several restated periods and unusually large special charges, so investors should place greater emphasis on recurring operating cash flow than on quarterly GAAP net income alone.

• Revenue has trended higher. Reported revenue increased from approximately $475 million in late 2022 to $679.3 million in Q2 2026. Q2 2026 revenue rose about 2% from Q1 2026 and 10% from the restated Q2 2025 level.
• Operating cash flow remains a major strength. Net cash from operating activities was $361.1 million in Q2 2026, compared with $260.9 million in Q1 2026 and $363.5 million in Q2 2025. Operating cash flow has remained positive in every reported quarter provided since Q1 2023.
• Cash liquidity has improved substantially. Cash and equivalents rose to $1.63 billion at June 30, 2026, from only $72.0 million at the end of 2022. Restricted cash added another $91.9 million, giving Healthpeak a sizable liquidity cushion, although part of the increase reflects financing and investment activity.
• Core capital spending is covered by operating cash flow. Q2 2026 operating cash flow exceeded $42.1 million of property and equipment purchases and $210.3 million of common dividends, leaving cash available for debt management and other uses.
• Investing cash flow is highly variable. Healthpeak generated $132.6 million from investing activities in Q2 2026, after using $638.6 million in Q1. The swings were driven primarily by purchases and sales of investment securities rather than by changes in property development spending.
• Asset growth has been significant. Total assets increased to $21.68 billion in Q2 2026 from $15.77 billion at the end of 2022. Net premises and equipment also grew from $13.02 billion to $16.86 billion, indicating expansion of the company’s real estate base, though the higher asset base has been accompanied by greater debt.
• Interest costs are pressuring earnings. Long-term debt interest expense increased to $92.3 million in Q2 2026 from $49.4 million in Q4 2022. Net interest expense widened to $70.5 million from $43.1 million over the same comparison, limiting the benefit of higher revenue.
• Debt and liabilities have risen faster than the balance sheet’s overall strength. Total debt was approximately $10.0 billion at June 30, 2026, versus about $6.6 billion at the end of 2022. Total liabilities reached $12.18 billion, or roughly 56% of total assets, compared with about 54% at year-end 2022.
• GAAP earnings remain inconsistent. Net income attributable to common shareholders fell to $52.7 million, or $0.08 per diluted share, in Q2 2026 from $193.5 million, or $0.28 per share, in Q1. The company also reported a $117.3 million common-shareholder loss in Q3 2025, demonstrating substantial quarter-to-quarter volatility.
• Large special charges continue to distort profitability. Other special charges totaled $333.1 million in Q2 2026 and $323.9 million in Q1, following $276.2 million in Q2 2025. Restructuring and other nonrecurring items have therefore remained material, making reported net income a less reliable measure of ongoing performance.

Overall, the statements point to a company with growing assets, improving liquidity and durable operating cash flow. However, the combination of rising debt, higher interest expense, recurring special charges and uneven GAAP earnings creates meaningful risk. Investors should monitor whether revenue growth and operating cash flow can continue to support the dividend while Healthpeak reduces refinancing needs and controls its cost of capital.